Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000692 · ClinicalTrials.gov registry record · Phase 1

Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex

A Phase 1 study, sponsored by G D Searle.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target

NCT00000692: Completed Phase 1 study, sponsored by G D Searle.

NCT00000692 is a Phase 1 study that has completed, run by G D Searle. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000692, a Phase 1 study, has completed, sponsored by G D Searle.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target

Study Summary

To determine the following about the use of SC-48334 in patients with AIDS and advanced AIDS related complex (ARC): 1\. The largest maximum tolerated dose (MTD); 2. Effectiveness against HIV; 3. Pharmacokinetics - how fast SC-48334 reaches the bloodstream, what concentration is reached, and how long it remains in the patient's blood. SC-48334 is a chemical that prevents the biochemical actions of certain enzymes in the body, and recent studies have shown that it may also prevent the activity of HIV. The study will attempt to show whether SC-48334 can safely and effectively break the cycle of HIV infection in AIDS and advanced ARC by progressively eliminating HIV.

Interventions

  • DRUG Butyldeoxynojirimycin

Trial Details

FieldValue
Enrollment Target 48 participants
Phase Phase 1
G D Searle

3 total trials

What the finished NCT00000692 record still lists

NCT00000692 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).

The record links to 0 conditions, and to 1 intervention - of which Butyldeoxynojirimycin is the first listed.

NCT00000692 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00000692 about?

NCT00000692 is a clinical study titled "Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex". To determine the following about the use of SC-48334 in patients with AIDS and advanced AIDS related complex (ARC): 1\. The largest maximum tolerated dose (MTD); 2. Effectiveness against HIV; 3. Pharmacokinetics - how fast SC-48334 reaches the bloodstream, what concentration is reached, and how lon...

What is the current status of trial NCT00000692?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants.

What interventions are being tested in trial NCT00000692?

The interventions under investigation include: Butyldeoxynojirimycin (DRUG).

Who is sponsoring clinical trial NCT00000692?

This trial is sponsored by G D Searle, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00000692's enrollment target sits among peer trials

48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Source: ClinicalTrials.gov NCT00000692, the US trial registry maintained by the National Library of Medicine. NCT00000692 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.